Glicina-alanil-l-fenilalanina

Glycine-Alanyl-L-Phenylalanine (Gly-Ala-Phe)

1. Identity and Chemical Characterization

Glycine-alanyl-L-phenylalanine, commonly abbreviated Gly-Ala-Phe or rendered in single-letter code as GAF, is a naturally occurring tripeptide composed of three proteinogenic amino acids joined in sequence by peptide bonds: glycine (Gly) at the N-terminus, L-alanine (Ala) in the central position, and L-phenylalanine (Phe) at the C-terminus. PubChem records it under CID 6992494 with the molecular formula C₁₄H₁₉N₃O₄. All three constituent residues are alpha-amino acids; with the exception of glycine, all amino acids can exist in both L- and D-isoforms, and the specific designation "L-phenylalanine" in the name confirms that the phenylalanine residue carries the biologically standard L-configuration.

The compound belongs to the broader chemical class of bioactive food-derived peptides — short peptide fragments released from intact dietary proteins by enzymatic proteolysis during digestion or food processing. When food proteins are digested, a myriad of variously sized peptides, from di- and tripeptides to higher-molecular-weight polypeptides, is released into the lumen of the digestive tract, and some may be partially resistant to further digestion. Gly-Ala-Phe is one of the many thousands of tripeptides that can in principle arise from such hydrolysis of common dietary proteins containing glycine, alanine, and phenylalanine in the appropriate sequence.

Sequentially distinct isomers sharing the same three residues but in different order — such as Ala-Gly-Phe (PubChem CID 11231669) and Phe-Ala-Gly (PubChem CID 71728365) — share the identical molecular formula C₁₄H₁₉N₃O₄ but are chemically and biologically distinct compounds with different stereochemical relationships, conformational properties, and receptor interactions. These isomers should not be confused with Gly-Ala-Phe.

1.1 Common Forms and Preparations

As a supplement ingredient, Gly-Ala-Phe is typically encountered as a chemically synthesized peptide of high purity, produced by solid-phase or solution-phase peptide synthesis methods. In food and biochemical research contexts, it can also arise through enzymatic hydrolysis of protein-rich raw materials. Enzymatic hydrolysis of food proteins is the process of breaking down food proteins by the action of proteolytic enzymes at a given temperature and pH; in the food industry, enzymatic hydrolysis is the most common technique employed for the liberation of bioactive peptides from proteins. The compound can also be generated by microbial fermentation of protein substrates, where endogenous and exogenous proteases act on protein chains to liberate short peptide sequences.

Commercially, the tripeptide is available primarily as a dry powder (lyophilized or spray-dried) for use in research and formulation contexts. In nutritional supplement products it generally appears as part of protein hydrolysate blends rather than as an isolated single-ingredient preparation, reflecting the reality that enzymatic hydrolysis of food proteins generates complex mixtures of peptides rather than a single defined sequence.

2. Natural Sources

Gly-Ala-Phe does not derive from a single botanical or zoological source; instead, it is a fragment peptide that can be released from any protein containing a Gly-Ala-Phe sequence motif. The likelihood of its release depends on the amino acid composition and sequence of the parent protein, as well as the specificity of the proteases involved. Proteins particularly rich in the three constituent residues include:

• Collagen and gelatin: Glycine makes up about 35% of the amino acid content of collagen and enables the tight coiling of the collagen triple helix. Collagen also contains substantial alanine and phenylalanine, making collagen hydrolysates a plausible source of Gly-Ala-Phe fragments upon proteolytic digestion.
• Milk and dairy proteins (caseins and whey): Many peptides that remain encrypted within the primary structure of the protein are released upon digestion and have been shown to influence multiple body systems. Casein and whey proteins contain all three amino acid residues and are extensively characterized sources of bioactive peptide fragments.
• Meat, fish, and egg proteins: The presence of phenylalanine and tryptophan is significant in many food sources, which include wheat germ, oats, dairy products, meats, poultry, nuts, and seeds. Proteins from these sources contain glycine, alanine, and phenylalanine and can yield Gly-Ala-Phe upon hydrolysis.
• Legumes and plant proteins: Soy, pea, wheat, and rice proteins are among the plant-derived sources from which bioactive peptide fragments containing these three residues may arise. Antihypertensive and other bioactive peptides have been identified from protein hydrolysates of various food products, including soybean, cereals, potatoes, nuts, vegetables, dairy products, eggs, and meat proteins.

3. Traditional and Historical Use

Glycine-alanyl-L-phenylalanine as a chemically defined, isolated tripeptide entity has no documented history of traditional or ethnomedical use. The concept of isolating and characterizing specific peptide sequences from protein hydrolysates did not exist prior to the development of modern analytical chemistry and peptide science in the twentieth century. No traditional medical system — including Ayurveda, Traditional Chinese Medicine, Greco-Roman medicine, or Indigenous pharmacopoeias — identified, named, or intentionally prepared this compound.

What does carry a documented historical context is the use of protein hydrolysates and fermented protein-rich foods, which would have contained Gly-Ala-Phe among many other peptide fragments without knowledge of its presence. Fermented dairy products, bone broths, fermented fish sauces, and enzyme-treated grain preparations have been consumed across cultures for millennia. The therapeutic properties attributed to such preparations — general strengthening, digestive support, wound healing — were not ascribed to any specific peptide constituent but to the food matrix as a whole.

The individual amino acids that constitute Gly-Ala-Phe have longer histories of scientific investigation. Glycine was discovered in 1820 by French chemist Henri Braconnot when he hydrolyzed gelatin by boiling it with sulfuric acid; he originally called it "sugar of gelatin," but French chemist Jean-Baptiste Boussingault showed in 1838 that it contained nitrogen. Glycine is a white, sweet-tasting crystalline solid, leading to its name from the Greek word glykys, meaning "sweet."

Phenylalanine, alanine, and glycine as free amino acids have been incorporated into dietary supplement formulations since the mid-to-late twentieth century, particularly as their biochemical roles in neurotransmitter synthesis, energy metabolism, and protein structure became established. DL-phenylalanine (DLPA) is marketed as a nutritional supplement for its purported analgesic and antidepressant activities, which have been supported by clinical trials. The combination of these residues into a defined tripeptide for supplementation purposes is a more recent development, driven by the broader scientific and commercial interest in food-derived bioactive peptides as nutraceutical ingredients.

4. Key Constituents and Active Compounds

Gly-Ala-Phe is itself the primary active entity of interest when this ingredient is supplemented. Its biological activity, to the extent it exists, is a property of the intact tripeptide sequence as well as the amino acids released upon its complete hydrolysis in the body. The compound's pharmacological and nutritional profile is therefore best understood through the established biochemistry of its three constituent amino acids and through general principles of bioactive peptide science.

4.1 Glycine (Gly)

Glycine is the simplest amino acid in nature, serving as a major component in proteins like collagen and functioning as an inhibitory neurotransmitter in the spinal cord and brain stem. Beyond its structural role, glycine functions as an inhibitory neurotransmitter in the central nervous system, particularly in the spinal cord and brainstem, where it helps regulate motor and sensory signals.

Glycine acts as a major agonist for glycine receptors (GlyRs) and as a coagonist for NMDA-type glutamate receptors. When GlyRs are activated in the adult CNS, it leads to increased chloride conductance of the postsynaptic cell, resulting in hyperpolarization and inhibition of the postsynaptic neuron. Beyond neurotransmission, glycine serves as a key precursor for the synthesis of other important biomolecules, including the porphyrins that form heme in blood and the purines used to build DNA and RNA.

Of the total amino acid content in the human body, 11.5% is represented by glycine, and 20% of the total amino acid nitrogen in body proteins is from glycine. In collagen, glycine is located at every third position; glycine residues bring together the triple helix of the collagen. Additionally, tumor necrosis factor, inflammation, and activation of macrophages are inhibited by glycine. Glycine also reduces alcohol-induced liver damage and removes lipid peroxidation reperfusion injury and glutathione deficiency caused by several types of hepatotoxins.

4.2 L-Alanine (Ala)

Alanine is a non-essential aliphatic amino acid with a central role in energy and nitrogen metabolism. Alanine is the primary amino acid that supplies carbon atoms for glucose by transamination to pyruvate. Alanine also serves a major role in transporting amino acid nitrogen from tissues to the liver for disposal in the urea cycle.

This function is formalized in the glucose-alanine cycle (Cahill cycle): alanine is synthesized and secreted from the skeletal muscle as a substrate for gluconeogenesis in the liver; alanine released from skeletal muscle is used as a substrate for gluconeogenesis in the liver; ALT catalyzes the reaction to form pyruvate from alanine in the liver, which is known as the "glucose-alanine cycle." The classical description of this cycle further notes that alanine is quantitatively the primary amino acid released by muscle and extracted by the splanchnic bed in postabsorptive as well as prolonged fasted man, and the hepatic capacity for conversion of alanine to glucose exceeds that of all other amino acids.

The role of alanine in glucose homeostasis is well established, though the relative contributions of hepatic gluconeogenesis from alanine versus recycling of glucose carbon have been revisited: recent research suggests that because the main substrate for alanine synthesis is pyruvate formed during glycolysis, alanine should instead be considered as a substance that ensures glucose recycling between the liver and muscles via the "alanine cycle," rather than strictly a substrate for gluconeogenesis.

4.3 L-Phenylalanine (Phe)

Phenylalanine is an essential aromatic amino acid that must be obtained from the diet. The daily need for the essential amino acid L-phenylalanine for protein synthesis is about 10 mg/kg body weight. A principal function of phenylalanine is its conversion into tyrosine and subsequently dopamine, one of the major neurotransmitters.

The metabolic pathway is precisely characterized: through an irreversible reaction, the liver enzyme phenylalanine hydroxylase (PAH) converts phenylalanine into tyrosine. L-phenylalanine is biologically converted into L-tyrosine, another one of the DNA-encoded amino acids. L-tyrosine in turn is converted into L-DOPA, which is further converted into dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline). Phenylalanine uses the same active transport channel as tryptophan to cross the blood-brain barrier. Additionally, phenylalanine serves as a precursor for the biosynthesis of melanin.

5. Mechanisms of Absorption and Bioavailability

A critical determinant of Gly-Ala-Phe's potential biological activity is whether the intact tripeptide survives luminal digestion to be absorbed in its intact form, or whether it is hydrolyzed to free amino acids before absorption. This question is central to all bioactive peptide science and determines whether effects, if any, are attributable to the tripeptide sequence itself or merely to its constituent amino acids.

Bioactive di/tripeptides are among the most efficient structural units that can cross the intestinal barrier and reach the circulation, owing to their small molecular size and compact conformation. Evidence indicates that more than 70% of protein digestion products in the gastrointestinal tract are absorbed in the form of di/tripeptides, primarily via a specialized proton-coupled transport system.

The key transport system is the oligopeptide transporter 1 (PepT1 / SLC15A1): the key mediator of this absorption process is peptide transporter 1 (PepT1), a proton-dependent oligopeptide transporter that is highly expressed at the brush-border membrane of intestinal epithelial cells. The intestinal peptide transporter 1 (PepT1) was first identified in 1994. It plays a crucial role in the absorption of small peptides including not only more than 400 different dipeptides and 8,000 tripeptides digested from dietary proteins but also a repertoire of structurally related compounds and drugs.

The proton-coupled uptake of more than 8,000 different di- and tripeptides is performed by the high-capacity/low-affinity peptide transporter isoform PepT1 (SLC15A1). Both PepT isoforms have a broad substrate pattern that includes mostly all di- and tripeptides formed from L-alpha amino acids, as well as a large variety of derivatives, including drugs such as beta-lactam antibiotics, selected angiotensin-converting enzyme inhibitors, protease inhibitors, and antivirals.

The binding cavity of PepT1 imposes a structural size limit: the peptide binding cavity of PepT1 is reported to be approximately 13 × 12 × 11 Å, which limits the attachment to only di- and tripeptides, while being sterically restrictive for peptides with more than tetrapeptide length. Gly-Ala-Phe, as a tripeptide, falls squarely within the substrate profile that PepT1 can transport. However, whether a meaningful fraction of an orally ingested Gly-Ala-Phe dose survives luminal peptidases to be presented to PepT1 intact is not established by available published data specific to this tripeptide.

Di/tripeptide transport efficiency is influenced by peptide structure, and some bioactive peptides, such as the egg protein-derived tripeptide IRW, are naturally resistant to digestive enzymes — a property that dramatically enhances their oral bioavailability. Whether Gly-Ala-Phe shares this resistance or is readily hydrolyzed in the gut lumen has not been reported in the peer-reviewed literature reviewed here.

6. Body Systems and Health Areas of Association

Because Gly-Ala-Phe has not been the subject of dedicated human clinical trials as of the sources available, its associations with specific body systems are inferred from: (a) the well-established roles of its three constituent amino acids in human physiology, and (b) general principles of bioactive tripeptide science. The following sections describe these associations with appropriate characterization of evidence strength.

6.1 Central Nervous System and Neurotransmitter Synthesis

The phenylalanine residue provides the most direct neuropharmacological rationale for interest in this tripeptide. Following absorption and hydrolysis, liberated L-phenylalanine can enter catecholamine biosynthesis: phenylalanine is also the precursor of the amino acid L-tyrosine, which itself is needed for the synthesis of proteins, compounds acting as neurotransmitters and hormones (adrenaline, noradrenaline, and dopamine), and melanin. The enzyme phenylalanine hydroxylase (PHA), which is responsible for this conversion, uses tetrahydropterin (BH4) as a cofactor.

The glycine residue also carries neurological relevance: glycine functions as an inhibitory neurotransmitter in the central nervous system, particularly in the spinal cord and brainstem, where it helps regulate motor and sensory signals. Disruption of glycine signaling can lead to severe neurological disorders and motor dysfunction. In the central nervous system, glycine plays a crucial role as neurotransmitter, thereby controlling intake of food, behavior, and complete body homeostasis.

6.2 Connective Tissue and Musculoskeletal System

The glycine content is particularly relevant for connective tissue support. In collagen, glycine residues stabilize the helical structure of the collagen. Most proteins incorporate only small quantities of glycine; a notable exception is collagen, which contains about 35% glycine due to its periodically repeated role in the formation of collagen's helix structure in conjunction with hydroxyproline. Alanine is also found in collagen and connective tissue proteins, making the amino acid composition of Gly-Ala-Phe broadly consistent with connective tissue nutritional support rationales that are commonly cited for protein hydrolysate preparations.

6.3 Glucose and Energy Metabolism

The alanine residue implicates Gly-Ala-Phe in gluconeogenic and energy-metabolic pathways. Alanine is quantitatively the primary amino acid released by muscle and extracted by the splanchnic bed in postabsorptive as well as prolonged fasted man, and the hepatic capacity for conversion of alanine to glucose exceeds that of all other amino acids. Additionally, glycine functions as a neurotransmitter in the CNS to regulate body homeostasis, immune function, production of superoxide, and synthesis of cytokines by altering intracellular Ca²⁺ levels; it is also due to its ability to enhance insulin secretion, as evident in its effect on postprandial glucose concentration.

6.4 Immune Function and Inflammation

Glycine has documented immunomodulatory properties at the level of the free amino acid: tumor necrosis factor, inflammation, and activation of macrophages are inhibited by glycine. Glycine lowers the level of superoxide ions from neutrophils through glycine-gated chloride channels. Whether these effects extend to glycine delivered in tripeptide form depends on the degree of intestinal hydrolysis, which is not yet characterized for Gly-Ala-Phe specifically.

More broadly, the immunomodulatory activity of food-derived peptides is recognized in the scientific literature: the immunomodulatory effect of isolated peptides is often related to the structure and properties of amino acids. The common hydrophobic amino acids in immunomodulatory peptides are glycine, leucine, proline, phenylalanine, and pentanine, which is notable given that Gly-Ala-Phe contains both glycine and phenylalanine.

6.5 Mood, Cognition, and Neurological Health

The catecholamine-precursor pathway of L-phenylalanine provides a theoretical basis for effects on mood and cognitive function. DL-phenylalanine (DLPA) is marketed as a nutritional supplement for its purported analgesic and antidepressant activities, which have been supported by clinical trials. DL-phenylalanine is a mixture of D-phenylalanine and L-phenylalanine. The reputed analgesic activity of DL-phenylalanine may be explained by the possible blockage by D-phenylalanine of enkephalin degradation by the enzyme carboxypeptidase A. These data pertain to free DLPA as a supplement, however, not to Gly-Ala-Phe.

7. Scientific Evidence by Area of Use

Critical note on evidence level: As of the sources identified through systematic searches of PubMed/PMC and related databases, there are no published peer-reviewed human clinical trials or systematic reviews examining Gly-Ala-Phe (glycine-alanyl-L-phenylalanine) as a discrete supplement ingredient in human subjects. The compound appears in chemical supplier catalogs and PubChem as a characterized substance, but has not been the subject of dedicated pharmacological or clinical investigation in the literature identified. All evidence below is therefore either: (a) in vitro or animal-level data on the intact peptide, or (b) clinical/human data on free amino acid constituents, which are relevant but not directly transferable to the tripeptide form.

7.1 Free L-Phenylalanine: Analgesic and Antidepressant Use (Clinical Evidence, Moderate)

DL-phenylalanine (DLPA) is marketed as a nutritional supplement for its purported analgesic and antidepressant activities, which have been supported by clinical trials. These trials, noted in reference literature, involve the free amino acid mixture DLPA rather than Gly-Ala-Phe, and the active analgesic component is the D-enantiomer (which is not present in the tripeptide, which contains only the L-form). The mechanism of DL-phenylalanine's supposed antidepressant activity may be accounted for in part by the precursor role of L-phenylalanine in the synthesis of the neurotransmitters norepinephrine and dopamine. This evidence is only partially relevant to Gly-Ala-Phe, which contains the L-form only and in peptide-bound rather than free form. Evidence strength: moderate for free DLPA supplements; not established for Gly-Ala-Phe specifically.

7.2 Free L-Phenylalanine: Appetite Regulation (Clinical Evidence, Preliminary)

In two studies of 52 women, mega doses of L-phenylalanine (10 g) reduced food intake by 11–15%; the effects depended on dietary habits and the phase of the menstrual cycle. It also boosts the release of CCK, a hormone that reduces appetite. These findings involve the free amino acid at a high dose (10 g), not the tripeptide form, and cannot be directly extrapolated to Gly-Ala-Phe. Evidence strength: preliminary; studies are small, dosing is extremely high, and are not specific to the tripeptide.

7.3 Free L-Phenylalanine and Parkinson's Disease: Dopamine Precursor Hypothesis (Theoretical)

L-phenylalanine is a precursor for dopamine, a vital neurotransmitter that's deficient in Parkinson's disease; this fact has inspired some research in the past, but the potential benefits of phenylalanine for this indication are still in the domain of theory. No clinical trials using Gly-Ala-Phe for this purpose have been identified. Evidence strength: theoretical/preclinical only.

7.4 Glycine: Sleep Quality (Clinical Evidence, Emerging)

Free glycine as a supplement has been evaluated in small human clinical trials for effects on sleep quality. In the central nervous system, glycine plays a crucial role as a neurotransmitter, thereby controlling intake of food, behavior, and complete body homeostasis. Published trials on glycine supplementation for sleep improvement exist in the literature but involve free glycine at doses of approximately 3 g, not peptide-bound glycine. Whether the glycine residue in Gly-Ala-Phe delivers equivalent systemic glycine after hydrolysis — and whether an intact tripeptide confers the same CNS effects — has not been evaluated. Evidence strength for free glycine on sleep: emerging (small RCTs). Evidence for Gly-Ala-Phe specifically: none identified.

7.5 Food-Derived Peptides in General: Bioactive Properties (Preclinical Evidence, Growing)

The broader scientific context for Gly-Ala-Phe's inclusion in supplements is the well-documented phenomenon of bioactive food-derived peptides. Many peptides that remain encrypted within the primary structure of the protein, only to be released upon digestion, have been shown to influence multiple body systems, and some share structural motifs with endogenous peptides known to modulate physiological function. However, the European Food Safety Authority rejected health claims for milk tripeptides IPP and VPP because of insufficient human research in the reported literature and the lack of recommended dosage evidence of the effect mechanism. Therefore, whether it is a nutritional product or a functional or therapeutic product, clinical trials must be conducted to determine the safety of the biologically active peptide, as well as the delivery method and effect dose. This regulatory precedent illustrates that even well-studied food-derived tripeptides face stringent evidentiary requirements for health claims — a bar that Gly-Ala-Phe has not yet reached. Evidence strength: general class effect is well-supported; specific evidence for Gly-Ala-Phe is absent.

7.6 Phenylalanine Metabolism: Association with Nutritional Risk and Mortality (Observational Clinical Evidence)

Elevated phenylalanine serum level is a surrogate marker of whole-body proteolysis and has been associated with increased mortality in critically ill patients. Tyrosine is a metabolite of phenylalanine and serves as a precursor of thyroid hormones and catecholamines with important functions in the oxidative stress response, among others. This association was examined in the context of the EFFORT randomized controlled trial: this is a secondary analysis of the Effect of Early Nutritional Support on Frailty, Functional Outcomes, and Recovery of Malnourished Medical Inpatients Trial (EFFORT), a randomized controlled trial investigating individualized nutritional support compared to standard care in patients at risk of malnutrition. The primary outcome was 30-day all-cause mortality. These findings relate to endogenous phenylalanine levels as biomarkers rather than to phenylalanine supplementation via Gly-Ala-Phe. Evidence strength: observational; relevant to phenylalanine physiology but not to the tripeptide supplement.

8. Dosage Forms and Reported Dosages

No published peer-reviewed clinical trials have established dosage recommendations or tested specific dose ranges for Gly-Ala-Phe as an isolated supplement ingredient in humans. The following dosages are reported in the scientific literature for the constituent free amino acids and are provided strictly as contextual reference; they do not represent established dosages for the tripeptide:

• L-Phenylalanine (free amino acid, not tripeptide-bound): The daily need for the essential amino acid L-phenylalanine for protein synthesis is approximately 10 mg/kg body weight. In the appetite regulation studies cited above, doses of up to 10 g were used in studies of 52 women. In a described nutraceutical formulation, 125 mg L-phenylalanine was used as part of a combination supplement in particular adult human dosing embodiments determined through experimentation.
• Glycine (free amino acid, not peptide-bound): Glycine is Generally Recognized as Safe (GRAS) by the FDA as a food additive. It is produced industrially by chemical synthesis for use as a food additive, a nutritional supplement, and an intermediate in the manufacture of various products. Supplemental doses used in sleep research trials are in the range of 3 g per day, as reported in the broader literature, though specific dosages were not confirmed in the sources retrieved here.

Because the molar ratios of the three amino acids in Gly-Ala-Phe are fixed by its molecular structure (1:1:1), the effective delivery of each amino acid from a given dose of the tripeptide is determined by its molecular weight (C₁₄H₁₉N₃O₄, MW approximately 293.32 g/mol) and by the efficiency of intestinal hydrolysis to free amino acids — neither of which has been quantified clinically for this compound.

9. Safety Considerations and Interactions

No dedicated safety or toxicology studies for Gly-Ala-Phe as an isolated tripeptide supplement have been identified in the peer-reviewed literature. Safety inferences are therefore drawn from the well-established profiles of its constituent amino acids.

9.1 Phenylketonuria (PKU) — Critical Contraindication

The most important safety consideration for any phenylalanine-containing compound is phenylketonuria (PKU). Phenylketonuria (PKU) is an inherited, autosomal recessive metabolic disorder, caused by reduced conversion of phenylalanine to tyrosine, due to deficient phenylalanine hydroxylase (PAH) activity, resulting in increased blood phenylalanine levels. Without treatment, PKU results in severe mental retardation, microcephaly, epilepsy, and other neurological symptoms. Management of phenylketonuria is mainly achieved through dietary control with limited intake of phenylalanine from food. Because Gly-Ala-Phe contains an L-phenylalanine residue that would be liberated upon hydrolysis, it is contraindicated in individuals with PKU.

9.2 Phenylalanine and Neurotransmitter Interactions

Phenylalanine uses the same active transport channel as tryptophan to cross the blood-brain barrier. This means that high doses of phenylalanine-containing supplements could competitively reduce brain tryptophan uptake and potentially affect serotonin synthesis — a pharmacokinetic interaction relevant when phenylalanine is taken alongside tryptophan, 5-HTP, or serotonergic medications. This is a theoretical concern at high doses; the magnitude of this effect from Gly-Ala-Phe supplementation at typical doses is not established.

High phenylalanine-to-tyrosine ratios may reduce dopamine synthesis, a paradoxical effect of excessive phenylalanine intake where the substrate overwhelms the hydroxylase enzyme's regulatory capacity.

9.3 Potential Interaction with MAOIs and Serotonergic Drugs

As a catecholamine precursor, L-phenylalanine may interact with monoamine oxidase inhibitors (MAOIs) by augmenting the production of dopamine, norepinephrine, and epinephrine at doses where the substrate effect is significant. This interaction has been documented for phenylalanine-rich foods and free phenylalanine supplements; whether the tripeptide form poses equivalent risk is unknown but theoretically possible if hydrolysis to free phenylalanine occurs efficiently.

9.4 Glycine and NMDA Receptor Co-Agonism

Glycine acts as a major agonist for glycine receptors (GlyRs) and as a coagonist for NMDA-type glutamate receptors. At supraphysiological concentrations, excessive glycine could in theory modulate NMDA receptor activity, which may be pharmacologically relevant in individuals taking NMDA receptor modulators (e.g., memantine, ketamine, or certain antiepileptics). The clinical significance of this interaction at dietary supplement doses has not been well characterized for free glycine, let alone for peptide-bound glycine.

9.5 General Peptide Safety Considerations

Whether it is a nutritional product, a functional product, or a therapeutic product, the target of biologically active peptides is human, so clinical trials must be conducted to determine the safety of the biologically active peptide, as well as the delivery method and effect dose. In the absence of such trials for Gly-Ala-Phe, its safety profile at various doses in different populations (e.g., pregnant women, those with renal impairment, those with hepatic disease affecting gluconeogenesis from alanine) remains formally uncharacterized.

9.6 Alanine and Glucose Metabolism

Insulin inhibits gluconeogenesis by reducing hepatic alanine uptake; in contrast, in diabetes, an increase in hepatic alanine extraction is observed in the face of diminished circulating substrate. This suggests that large supplemental doses of alanine-containing compounds could have unpredictable effects on glucose homeostasis in individuals with diabetes or insulin resistance, though the clinical relevance of typical supplement doses is not established.

10. Summary of Evidence Strength

• Chemical identity: Well-established; PubChem-confirmed molecular formula and structure.
• Natural occurrence as food-derived peptide fragment: Plausible and consistent with well-documented peptide release from protein hydrolysis, but specific identification of Gly-Ala-Phe in characterized food hydrolysates has not been confirmed in the sources reviewed.
• Intestinal absorption via PepT1: Well-supported mechanism for tripeptides as a class; specific transport data for Gly-Ala-Phe are absent.
• Constituent amino acid biochemistry: Extensively established across decades of peer-reviewed research.
• Clinical evidence for Gly-Ala-Phe as a supplement: None identified in peer-reviewed databases. All clinical associations are indirect, derived from free amino acid research.
• Safety data for Gly-Ala-Phe: Not formally characterized; PKU contraindication is definitive based on phenylalanine content.

References

• PubChem CID 6992494 — Gly-Ala-Phe (National Library of Medicine / NIH)
• PubChem CID 11231669 — Ala-Gly-Phe (National Library of Medicine / NIH)
• PubChem CID 71728365 — Phe-Ala-Gly (National Library of Medicine / NIH)
• Glycine — Wikipedia (citing primary literature including Braconnot 1820)
• Phenylalanine — Wikipedia
• Razak et al. (2017). Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review. Oxidative Medicine and Cellular Longevity. PMC5350494
• Beyond Protein Building Blocks: A Review of Biological Roles and Therapeutic Potential of Free Amino Acids. PMC12691759
• The Essentiality of Amino Acids in Healthiness and Disease State: Type II Diabetes as a Case Study. PMC12124235
• Glycine (Amino Acid) — ScienceDirect Topics (Encyclopedia of Food Sciences and Nutrition)
• Alanine — ScienceDirect Topics (Encyclopedia of Food Sciences and Nutrition)
• Phenylalanine — ScienceDirect Topics (Neuroscience overview)
• Origin and Roles of Alanine and Glutamine in Gluconeogenesis. PMC11241752
• PGC-1α regulates alanine metabolism in muscle cells. PMC5760032
• Felig P. (1970). Alanine: key role in gluconeogenesis. Science. PubMed 5411169
• Felig P. (1973). The glucose-alanine cycle. Metabolism.
• Chakrabarti S et al. (2018). Food-Derived Bioactive Peptides in Human Health: Challenges and Opportunities. PMC6265732
• Food-derived bioactive peptides: production, biological activities, opportunities and challenges. Food Chemistry: X. 2022
• Meisel H, FitzGerald RJ. (2000). Food-derived bioactive peptides — a new paradigm. Nutrition Research Reviews.
• Enhancing the Biological Activities of Food Protein-Derived Peptides Using Non-Thermal Technologies: A Review. PMC9265340
• Trends and applications of food protein-origin hydrolysates and bioactive peptides. PMC9635901
• Intestinal epithelial transport of bioactive di/tripeptides through PepT1: Molecular mechanism and influencing factors. Food Chemistry. 2025
• Regulation profile of the intestinal peptide transporter 1 (PepT1). PMC5726373
• Shen W, Matsui T. (2019). Intestinal absorption of small peptides: a review. International Journal of Food Science and Technology.
• Dalmasso G et al. (2008). PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. PMC2431115
• Transcriptional and functional regulation of the intestinal peptide transporter PEPT1. PMC3948552
• Peptide Transporter 1 is Responsible for Intestinal Uptake of the Dipeptide Glycylsarcosine. PMC3010518
• The effect of casein glycomacropeptide versus free synthetic amino acids for early treatment of phenylketonuria in a mice model. PMC8751992
• Association of phenylalanine and tyrosine metabolism with mortality and response to nutritional support: secondary analysis of EFFORT trial. PMC11588475
• Analysis of amino acids in Mucuna pruriens supplements using HILIC-TQMS. PMC12881161